3 Biotech Stocks on Track for 50% Returns (or More) by 2028 | Markets

The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.

High potential biotech stocks can be relatively easy to find when focusing on the right financial metrics and previous track records of success. Too often, prospective investors are wrapped up in the hopes and dreams that smaller biotech firms sell them. This results in investors taking on risks that are simply above their pay grade.

Moreover, certain forward looking statements regarding data and potential breakthroughs can be extremely misleading. This level of unpredictability regarding companies with little to no track record makes them extremely risky investments. Therefore, sticking with companies with previous success and strong financial performance is crucial to avoid losing money.

Now, let’s discover the top 3 high potential biotech stocks on track for 50% returns or more by 2028!

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX), a global leader in treatment of cystic fibrosis (CF), stands out as one of the top high potential biotech stocks to buy. While this is its bread and butter, the company is advancing its treatment pipeline in areas such as sickle cell disease and…